P19
Targeting colorectal liver metastasis by overcoming MYC-induced immune evasion
Project Leader
Research Focus
Nearly all MSS CRCs have an APC mutation, which leads to the overexpression of the MYC proto-oncogene. MYC promotes tumor growth and facilitates immune evasion, ultimately contributing to resistance against immunotherapy, yet MYC also impacts proliferation and function of T and B lymphocytes, making these processes dependent on MYC. P19 will explore whether selectively reducing MYC in colorectal liver metastases (CRLM) makes them detectable by the immune system, which TME-cells exhibit an immune-mediated response while dissecting the effect of MYC in tumor vs. immune cells.
Main Collaborations
- P01 Greten: Modulating CAF plasticity to enable immunotherapy of colorectal cancer:
- P03 Briquez/Fichtner-Feigl/Reuten: Metastasis predisposing extracellular matrix architecture in colorectal cancer:
- P10 Bengsch/Feuerstein: Targeting the intra-metastatic microbiome in colorectal cancer:
- P14 Kesselring/Minguet: The role of γδ T cells in the tumor microenvironment of colorectal cancer:
- P18 Buchholz/Farin: Identifying and overcoming CAR T cell barriers in the colorectal carcinoma microenvironment:
- S01 Berlin/Greten/Naschberger: Human tumor organoid biobanks for preclinical validation:
- S02 Reiss/Ritter: Spatial profiling of the tumor microenvironment in CRC:
- S03 Börries/Gupta: Research Information Infrastructure, Data Management and Bioinformatics Core:
